Dietary Intervention in Patients with a History of Melanoma
NCT ID: NCT03950635
Last Updated: 2024-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
13 participants
INTERVENTIONAL
2019-04-16
2024-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Whole-foods, fiber-rich diet rationale: Recent studies have shown that the gut microbiome (the trillions of bacteria that live in our intestines) can influence our immune system function. Diet plays a key role in shaping the gut microbiome. We will examine the effects of a whole-food, fiber-rich diet on the gut microbiome within patients with a history of melanoma.
Ketogenic diet rationale: The ketogenic diet is a very-low-carbohydrate, high-fat diet. The goal of this diet is to change the body's fuel source from carbohydrates to fat and to lower levels of insulin. We will examine the effects of a ketogenic diet to change metabolism within patients with a history of melanoma.
Who can participate?
To be eligible for the study, participants must meet the following criteria:
* Be at least 18 years old;
* Meet the study requirements for Body Mass Index (BMI);
* Have had melanoma within the last 5 years;
* Be cancer-free at the start of the trial;
* Have not received systemic therapy within the last year; and
* Have no medical issues that would make them unable to follow these eating plans.
Study Design:
Our study will enroll up to 10 participants to each diet (high-fiber or ketogenic). After screening, participants will have baseline assessment performed that will include collecting diet information, blood and fecal samples, and body composition information. Participants will then eat the provided diets for the next 6 weeks while coming in every 2 weeks for blood and stool specimen collection. Six (6)weeks after the diet intervention is complete, participants will come back to MD Anderson for one last end of study visit.
Who makes the meals?:
All calorie-containing food and beverages will be provided by either the MD Anderson Cancer Center Bionutrition Research Core or Savor Health (a third-party vendor contracted by MD Anderson).
Costs: There will be no cost to participate in this study.
Benefits:
All food and beverages you will eat as part of this study will be provided by the study and can be shipped directly to your home. The results will be used to help us design future dietary intervention trials in Melanoma patients receiving immunotherapy. Please note, participants can withdraw from the study at any time without consequences.
Study PI: Dr. Jennifer McQuade
NCT#: NCT03950635
Contact Info:
Melanoma Medical Oncology (713)-792-5500 [email protected]
Where: MD Anderson Cancer Center, Department of Melanoma Medical Oncology, Houston, TX
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (fiber-rich diet)
Patients consume a whole-foods, fiber-rich diet for 6 weeks.
Dietary Intervention
Consume whole-foods, fiber-rich diet
Questionnaire Administration
Ancillary studies
Group II (ketogenic diet)
Patients consume a high fat, low carbohydrate (ketogenic) diet for 6 weeks.
Dietary Intervention
Consume high fat, low carbohydrate (ketogenic) diet
Questionnaire Administration
Ancillary studies
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Intervention
Consume whole-foods, fiber-rich diet
Dietary Intervention
Consume high fat, low carbohydrate (ketogenic) diet
Questionnaire Administration
Ancillary studies
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index (BMI) 18.5-40 kg/m\^2.
* English-speaking.
* Self-reported willingness to exclusively eat the provided diets.
* Self-reported willingness to comply with scheduled visits, undergo venipuncture, provide stool samples.
* Creatinine (Cr) \< 1.5 mg/dL.
* Liver function tests (LFTs) 2 x upper limit of normal (ULN).
* Fasting glucose \< 125 mg/dL.
* Women of child-bearing (WOCP) potential must have negative urine pregnancy test (UPT) within 1 week prior to dual x-ray absorptiometry (DEXA) scan.
Exclusion Criteria
* Medical contraindications to the intervention diet as determined by the treating physician.
* Self-reported major dietary restrictions related to the intervention.
* Diagnosis of diabetes mellitus type I or type II that requires medical treatment.
* Unable or unwilling to undergo study procedures.
* Antibiotic use within the last 30 days (self-reported and/or noted by the treating physician).
* Regularly taking probiotics, fiber supplements, or bile acid sequestrants, exogenous ketones, weight loss supplements, appetite suppressants, carnitine supplements, creatine supplements or diuretics within the last 30 days (self-reported and/or noted by the treating physician).
* Currently following a ketogenic diet with \> 70% calories derived from fat or consuming \> 40 grams of fiber per day or a vegetarian or vegan diet.
* Current self-reported smoker or heavy drinker (defined as \> 14 drinks per week) or current self-reported illicit drug use.
* Pregnant or lactating.
* Low density lipoprotein (LDL) \> 200 mg/dL (within 28 days of screening).
* Triglycerides \> 350 mg/dL (within 28 days of screening).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer McQuade
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
MD Anderson Cancer Center Website
https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2018-0857.html
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-02496
Identifier Type: REGISTRY
Identifier Source: secondary_id
2018-0857
Identifier Type: OTHER
Identifier Source: secondary_id
2018-0857
Identifier Type: -
Identifier Source: org_study_id